Compound Profile
What Is Retatrutide?
Retatrutide (LY3437943) is a synthetic acylated peptide developed by Eli Lilly & Company. It is structurally engineered to function as a simultaneous agonist at three incretin and glucagon-related G protein-coupled receptors. Published research has investigated its multi-receptor pharmacology across the Phase 1 and Phase 2 TRIUMPH trial program, with Phase 3 data ongoing as of 2026.
Mechanistic Context
Retatrutide vs. Tirzepatide vs. Semaglutide — Receptor Targets
Peer-reviewed literature has investigated retatrutide's distinct receptor profile relative to earlier incretin compounds. The glucagon receptor axis — absent from both semaglutide and tirzepatide — represents the mechanistically novel dimension of published retatrutide research.
| Receptor Target | Semaglutide GLP-1 monoagonist |
Tirzepatide GLP-1/GIP dual |
Retatrutide GLP-1/GIP/GCG triple |
|---|---|---|---|
| GLP-1 Receptor (GLP-1R) | ✓ Primary target | ✓ Active | ✓ Active (EC₅₀ ≈ 0.775 nM) |
| GIP Receptor (GIPR) | ✗ Not targeted | ✓ Active | ✓ Highest potency (EC₅₀ ≈ 0.064 nM) |
| Glucagon Receptor (GCGR) | ✗ Not targeted | ✗ Not targeted | ✓ Active (EC₅₀ ≈ 5.79 nM) |
| Hepatic Glucagon Receptor Signaling | ✗ | ✗ | ✓ Investigated in liver oxidation pathway research |
| Regulatory status (as of 2026) | ✓ Approved pharmaceutical products exist in this monoagonist class | ✓ Approved pharmaceutical products exist in this dual-agonist class | — Investigational; not FDA-approved |
| Sequence Labs supply category | ✓ Research-grade RUO material only | ✓ Research-grade RUO material only | ✓ Research-grade RUO material only |
Published Research Areas
Active Areas of Retatrutide Investigation
Peer-reviewed literature has examined retatrutide across several intersecting pharmacological domains. The following areas reflect published research contexts — not claims about outcomes or human effects.
Independent testing has identified retatrutide as among the highest-risk compounds for adulteration and substitution in the research peptide market. Third-party testing of Peptide Sciences samples by Janoshik Analytical — conducted between late 2024 and early 2026 — detected quality inconsistencies and at least one confirmed counterfeit in their retatrutide inventory. Retatrutide was also specifically named in the FDA Warning Letter issued to Gram Peptides (March 31, 2026). Sequence Labs supplies retatrutide exclusively with batch-specific COA documentation from Krause Analytical (Austin, TX) — independent HPLC and mass spectrometry identity and purity verification on every lot. Verify any batch at any time via our COA Library.
Sequence Labs Supply
Research-Grade Retatrutide.
COA on Every Batch.
Given the heightened regulatory and purity scrutiny around retatrutide, Sequence Labs holds every lot to a higher documentation standard. All retatrutide is independently verified by Krause Analytical before release — with HPLC purity, mass spectrometry identity confirmation, and batch traceability published in the COA Library.
Laboratory Handling
Receiving, Storage & Documentation
Retatrutide ships as a sealed lyophilized research vial. Receiving, storage, and any subsequent laboratory preparation are governed by your institution’s protocols and the batch Certificate of Analysis. Sequence Labs does not provide reconstitution recipes, administration instructions, or human-use guidance.
For research use only. Not for human use or veterinary use. Retatrutide research material from Sequence Labs is not an FDA-approved drug and is not a substitute for any marketed medicine.
Frequently Asked Questions
Ready to Source Research-Grade Retatrutide?
Every batch independently verified by Krause Analytical. HPLC + mass spec COA published for each lot. For qualified researchers and laboratories only. Research use only — not for human use.